Qelbree
Brand name for viloxazine, a non-stimulant ADHD medication approved in 2021
As defined in Rethinking ADHD Treatment: The Power of Non-Stimulant Medication
Where it comes up · 1
Most important claims · 7 of 7Search all claims for “Qelbree” →
- In a comparative study of Strattera versus Qelbree, 85% of patients who had Qelbree added to their stimulant medication were able to taper off the stimulant after stabilizing on Qelbree, indicating that Qelbree alone was sufficient for many patients.Rethinking ADHD Treatment: The Power of Non-Stimulant Medication
- Viloxazine (Qelbree) significantly reduced executive function deficits in a published study, though this study was conducted in children and the results may not fully generalize to adults.Rethinking ADHD Treatment: The Power of Non-Stimulant Medication
- A 2023 comparative study found that viloxazine (Qelbree) was more effective than atomoxetine (Strattera) and worked faster, showing effects within about one week for children and two weeks for adults.Rethinking ADHD Treatment: The Power of Non-Stimulant Medication
- Atomoxetine (Strattera) and viloxazine (Qelbree) are both norepinephrine reuptake inhibitors that work by increasing norepinephrine in the prefrontal cortex, which secondarily increases dopamine and serotonin in that brain region.Rethinking ADHD Treatment: The Power of Non-Stimulant Medication
- Unlike stimulants, atomoxetine (Strattera) and viloxazine (Qelbree) must be taken daily because they require consistent dosing to maintain their effects.Rethinking ADHD Treatment: The Power of Non-Stimulant Medication
- Viloxazine (Qelbree) is still a brand-name medication, which means doctors often need to complete insurance authorizations for coverage, and some insurances require patients to try and fail atomoxetine (Strattera) first before approving viloxazine.Rethinking ADHD Treatment: The Power of Non-Stimulant Medication
- There are currently four FDA-approved non-stimulant medications for ADHD: clonidine (Kapvay), guanfacine (Intuniv), atomoxetine (Strattera), and viloxazine (Qelbree, approved in 2021).Rethinking ADHD Treatment: The Power of Non-Stimulant Medication